| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Transplantation Conditioning | 48 | 2019 | 323 | 7.16 | Why? |
| Hematopoietic Stem Cell Transplantation | 81 | 2021 | 2426 | 6.89 | Why? |
| Leukemia, Myeloid, Acute | 49 | 2020 | 676 | 6.33 | Why? |
| Graft vs Host Disease | 40 | 2019 | 501 | 5.09 | Why? |
| Unrelated Donors | 19 | 2019 | 187 | 2.93 | Why? |
| Transplantation, Homologous | 36 | 2019 | 757 | 2.33 | Why? |
| Antilymphocyte Serum | 9 | 2019 | 80 | 1.79 | Why? |
| Lymphocyte Transfusion | 4 | 2019 | 26 | 1.64 | Why? |
| Transplantation, Haploidentical | 13 | 2019 | 53 | 1.55 | Why? |
| Bone Marrow Transplantation | 10 | 2020 | 343 | 1.55 | Why? |
| Multiple Myeloma | 10 | 2020 | 1064 | 1.50 | Why? |
| Salvage Therapy | 5 | 2018 | 417 | 1.49 | Why? |
| Hepatic Veno-Occlusive Disease | 2 | 2018 | 25 | 1.46 | Why? |
| Polydeoxyribonucleotides | 2 | 2018 | 118 | 1.31 | Why? |
| Busulfan | 9 | 2019 | 22 | 1.31 | Why? |
| Peripheral Blood Stem Cell Transplantation | 7 | 2019 | 86 | 1.31 | Why? |
| Hematologic Neoplasms | 8 | 2021 | 2105 | 1.26 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2020 | 526 | 1.25 | Why? |
| Disease-Free Survival | 30 | 2019 | 1654 | 1.21 | Why? |
| Cyclophosphamide | 12 | 2019 | 387 | 1.15 | Why? |
| Thiotepa | 3 | 2018 | 4 | 1.12 | Why? |
| Myelodysplastic Syndromes | 4 | 2020 | 261 | 1.10 | Why? |
| Whole-Body Irradiation | 9 | 2018 | 42 | 1.06 | Why? |
| Leukemia | 5 | 2020 | 598 | 1.05 | Why? |
| Remission Induction | 19 | 2019 | 950 | 0.95 | Why? |
| Vidarabine | 6 | 2019 | 59 | 0.91 | Why? |
| Neoplasm Recurrence, Local | 6 | 2018 | 1063 | 0.88 | Why? |
| Myeloablative Agonists | 7 | 2018 | 57 | 0.86 | Why? |
| Leukemia, Myeloid | 2 | 2018 | 76 | 0.86 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2019 | 1573 | 0.82 | Why? |
| Transplantation, Autologous | 10 | 2020 | 364 | 0.80 | Why? |
| Azacitidine | 1 | 2019 | 42 | 0.79 | Why? |
| Hematologic Diseases | 4 | 2021 | 614 | 0.77 | Why? |
| Lymphoproliferative Disorders | 1 | 2020 | 110 | 0.75 | Why? |
| Allografts | 16 | 2020 | 761 | 0.75 | Why? |
| Tissue Donors | 8 | 2021 | 1679 | 0.72 | Why? |
| Globulins | 1 | 2018 | 90 | 0.69 | Why? |
| Siblings | 7 | 2019 | 226 | 0.69 | Why? |
| Cord Blood Stem Cell Transplantation | 5 | 2019 | 143 | 0.69 | Why? |
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 73 | 0.68 | Why? |
| Heterocyclic Compounds | 1 | 2017 | 64 | 0.68 | Why? |
| Stem Cell Transplantation | 3 | 2017 | 531 | 0.61 | Why? |
| Antineoplastic Agents, Alkylating | 4 | 2020 | 71 | 0.59 | Why? |
| Neoplasms, Second Primary | 4 | 2019 | 100 | 0.57 | Why? |
| Survival Rate | 24 | 2019 | 9206 | 0.56 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2017 | 403 | 0.54 | Why? |
| Fecal Microbiota Transplantation | 1 | 2019 | 372 | 0.54 | Why? |
| Recurrence | 18 | 2019 | 3675 | 0.53 | Why? |
| fms-Like Tyrosine Kinase 3 | 5 | 2019 | 43 | 0.50 | Why? |
| Dysbiosis | 1 | 2019 | 685 | 0.49 | Why? |
| Philadelphia Chromosome | 4 | 2019 | 38 | 0.48 | Why? |
| Histocompatibility Testing | 5 | 2019 | 219 | 0.47 | Why? |
| Survival Analysis | 18 | 2019 | 7592 | 0.46 | Why? |
| Registries | 17 | 2019 | 12327 | 0.45 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 1115 | 0.42 | Why? |
| Cyclosporine | 3 | 2019 | 449 | 0.41 | Why? |
| Iron Overload | 1 | 2012 | 113 | 0.41 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.38 | Why? |
| Lymphocyte Depletion | 4 | 2018 | 293 | 0.38 | Why? |
| Histocompatibility | 5 | 2018 | 53 | 0.36 | Why? |
| Immunoconjugates | 2 | 2018 | 90 | 0.35 | Why? |
| Perioperative Care | 1 | 2019 | 1329 | 0.35 | Why? |
| Hemoglobinuria, Paroxysmal | 2 | 2021 | 116 | 0.35 | Why? |
| Europe | 18 | 2020 | 12702 | 0.34 | Why? |
| HLA Antigens | 6 | 2019 | 830 | 0.34 | Why? |
| Middle Aged | 75 | 2021 | 270681 | 0.33 | Why? |
| Adult | 74 | 2021 | 244371 | 0.33 | Why? |
| Primary Myelofibrosis | 2 | 2019 | 144 | 0.32 | Why? |
| Anemia, Aplastic | 2 | 2018 | 167 | 0.32 | Why? |
| Retrospective Studies | 51 | 2019 | 105322 | 0.32 | Why? |
| T-Lymphocytes | 7 | 2021 | 6670 | 0.31 | Why? |
| Aged | 60 | 2021 | 215776 | 0.31 | Why? |
| Young Adult | 46 | 2021 | 93724 | 0.31 | Why? |
| Fibrinolytic Agents | 1 | 2018 | 1702 | 0.31 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.30 | Why? |
| Hodgkin Disease | 2 | 2018 | 204 | 0.30 | Why? |
| Immunotherapy, Adoptive | 2 | 2020 | 524 | 0.29 | Why? |
| Male | 78 | 2021 | 367725 | 0.28 | Why? |
| Female | 78 | 2021 | 380317 | 0.28 | Why? |
| Treatment Outcome | 30 | 2020 | 51732 | 0.27 | Why? |
| Follow-Up Studies | 16 | 2020 | 17020 | 0.27 | Why? |
| Survivors | 2 | 2018 | 2619 | 0.27 | Why? |
| Humans | 110 | 2021 | 930598 | 0.26 | Why? |
| Adolescent | 40 | 2019 | 86841 | 0.26 | Why? |
| Melphalan | 2 | 2020 | 46 | 0.26 | Why? |
| Alkylating Agents | 2 | 2019 | 12 | 0.25 | Why? |
| Ferritins | 1 | 2012 | 2055 | 0.25 | Why? |
| Immunosuppressive Agents | 6 | 2019 | 6331 | 0.24 | Why? |
| Acute Disease | 10 | 2019 | 6029 | 0.24 | Why? |
| Dexamethasone | 5 | 2019 | 2055 | 0.22 | Why? |
| Bortezomib | 2 | 2018 | 125 | 0.22 | Why? |
| Societies, Medical | 8 | 2020 | 6907 | 0.22 | Why? |
| Antigens, CD34 | 2 | 2017 | 125 | 0.21 | Why? |
| Thalidomide | 3 | 2018 | 247 | 0.21 | Why? |
| Lymphoma, Mantle-Cell | 1 | 2020 | 109 | 0.20 | Why? |
| Karyopherins | 1 | 2019 | 38 | 0.20 | Why? |
| Kaplan-Meier Estimate | 5 | 2020 | 4260 | 0.20 | Why? |
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 67 | 0.20 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.19 | Why? |
| Hydrazines | 1 | 2019 | 68 | 0.19 | Why? |
| Boronic Acids | 1 | 2018 | 30 | 0.19 | Why? |
| Benzylamines | 1 | 2017 | 8 | 0.19 | Why? |
| Gene Duplication | 1 | 2017 | 31 | 0.18 | Why? |
| Antineoplastic Agents | 4 | 2018 | 3550 | 0.18 | Why? |
| Adoptive Transfer | 1 | 2019 | 250 | 0.18 | Why? |
| Lymphoma, T-Cell, Peripheral | 1 | 2017 | 12 | 0.18 | Why? |
| Polycythemia Vera | 1 | 2019 | 113 | 0.18 | Why? |
| Thrombocythemia, Essential | 1 | 2019 | 141 | 0.18 | Why? |
| Adenine | 1 | 2020 | 463 | 0.17 | Why? |
| Fertility Preservation | 1 | 2019 | 121 | 0.17 | Why? |
| Chromosomes, Human, Pair 17 | 1 | 2017 | 13 | 0.17 | Why? |
| Lymphoma, B-Cell | 1 | 2019 | 166 | 0.17 | Why? |
| Blood Group Incompatibility | 1 | 2017 | 44 | 0.17 | Why? |
| Etoposide | 1 | 2018 | 115 | 0.17 | Why? |
| Receptors, KIR | 1 | 2018 | 167 | 0.16 | Why? |
| Isoantibodies | 1 | 2018 | 134 | 0.16 | Why? |
| Multivariate Analysis | 5 | 2018 | 5440 | 0.16 | Why? |
| Phenylurea Compounds | 1 | 2017 | 101 | 0.16 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.16 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 264 | 0.15 | Why? |
| Niacinamide | 1 | 2017 | 135 | 0.15 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.15 | Why? |
| Infertility | 1 | 2019 | 247 | 0.15 | Why? |
| Chronic Disease | 4 | 2018 | 5139 | 0.15 | Why? |
| Blood Component Removal | 1 | 2017 | 175 | 0.15 | Why? |
| Biomarkers, Tumor | 3 | 2019 | 1314 | 0.15 | Why? |
| Leukocytosis | 1 | 2017 | 280 | 0.14 | Why? |
| Triazoles | 1 | 2019 | 440 | 0.14 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 314 | 0.14 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.14 | Why? |
| Immune System Diseases | 1 | 2019 | 410 | 0.14 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2020 | 760 | 0.14 | Why? |
| Piperidines | 1 | 2020 | 795 | 0.14 | Why? |
| Steroids | 1 | 2020 | 904 | 0.13 | Why? |
| Lymphoma | 1 | 2019 | 522 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Prognosis | 13 | 2019 | 32490 | 0.13 | Why? |
| Candidemia | 1 | 2018 | 353 | 0.13 | Why? |
| Maintenance Chemotherapy | 3 | 2019 | 133 | 0.13 | Why? |
| Prospective Studies | 5 | 2019 | 43301 | 0.13 | Why? |
| Haplotypes | 1 | 2017 | 853 | 0.13 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.13 | Why? |
| B7-H1 Antigen | 1 | 2017 | 541 | 0.13 | Why? |
| Fetal Blood | 1 | 2017 | 573 | 0.13 | Why? |
| Cytomegalovirus | 1 | 2018 | 600 | 0.12 | Why? |
| Protein Kinase Inhibitors | 2 | 2019 | 1585 | 0.12 | Why? |
| Incidence | 8 | 2019 | 25622 | 0.11 | Why? |
| Janus Kinase Inhibitors | 1 | 2017 | 682 | 0.11 | Why? |
| Proportional Hazards Models | 6 | 2019 | 6543 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.10 | Why? |
| Safety | 1 | 2018 | 1583 | 0.10 | Why? |
| Autografts | 2 | 2019 | 78 | 0.10 | Why? |
| Graft Survival | 3 | 2017 | 587 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.10 | Why? |
| Tissue and Organ Procurement | 1 | 2020 | 1277 | 0.10 | Why? |
| Combined Modality Therapy | 4 | 2019 | 3395 | 0.10 | Why? |
| Delivery of Health Care | 3 | 2020 | 15909 | 0.09 | Why? |
| Time Factors | 6 | 2018 | 31397 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Neoplasm, Residual | 2 | 2018 | 147 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.09 | Why? |
| ABO Blood-Group System | 1 | 2017 | 995 | 0.09 | Why? |
| Chromosome Aberrations | 2 | 2018 | 54 | 0.09 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.08 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.08 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Long-Term Care | 1 | 2018 | 2047 | 0.08 | Why? |
| Bone Marrow | 2 | 2019 | 492 | 0.07 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.07 | Why? |
| Nuclear Proteins | 2 | 2018 | 321 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Chemotherapy, Adjuvant | 2 | 2017 | 606 | 0.07 | Why? |
| Mortality | 2 | 2018 | 7132 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Life Tables | 1 | 2003 | 46 | 0.07 | Why? |
| Developing Countries | 1 | 2019 | 4283 | 0.06 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.06 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.06 | Why? |
| Surveys and Questionnaires | 6 | 2019 | 43792 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.06 | Why? |
| Administration, Oral | 2 | 2019 | 2340 | 0.06 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.06 | Why? |
| Risk Assessment | 4 | 2018 | 25439 | 0.05 | Why? |
| Cross Infection | 2 | 2020 | 8675 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Cytomegalovirus Infections | 2 | 2018 | 667 | 0.05 | Why? |
| Mutation | 5 | 2019 | 12376 | 0.05 | Why? |
| Core Binding Factors | 1 | 2019 | 1 | 0.05 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.05 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.05 | Why? |
| Abnormal Karyotype | 1 | 2018 | 6 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2019 | 2324 | 0.05 | Why? |
| Karyotype | 1 | 2018 | 16 | 0.05 | Why? |
| Karyotyping | 1 | 2018 | 52 | 0.05 | Why? |
| Graft vs Leukemia Effect | 1 | 2017 | 3 | 0.05 | Why? |
| Drug Evaluation | 1 | 2018 | 100 | 0.05 | Why? |
| Feasibility Studies | 2 | 2019 | 3467 | 0.05 | Why? |
| Accreditation | 1 | 2020 | 203 | 0.04 | Why? |
| Leukocyte Reduction Procedures | 1 | 2017 | 19 | 0.04 | Why? |
| Intention to Treat Analysis | 1 | 2019 | 673 | 0.04 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2018 | 99 | 0.04 | Why? |
| Classification | 1 | 2017 | 55 | 0.04 | Why? |
| Immune Reconstitution | 1 | 2017 | 48 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Child | 7 | 2019 | 70012 | 0.04 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.04 | Why? |
| Horses | 1 | 2018 | 474 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| Roseolovirus Infections | 1 | 2017 | 131 | 0.04 | Why? |
| Confidence Intervals | 1 | 2018 | 744 | 0.04 | Why? |
| Polyomavirus Infections | 1 | 2017 | 156 | 0.04 | Why? |
| Drug Resistance, Neoplasm | 1 | 2019 | 447 | 0.04 | Why? |
| Plasma Cells | 1 | 2018 | 464 | 0.04 | Why? |
| CD3 Complex | 1 | 2016 | 237 | 0.04 | Why? |
| Office Visits | 1 | 2020 | 489 | 0.04 | Why? |
| Janus Kinase 2 | 1 | 2017 | 218 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Preventive Health Services | 1 | 2020 | 501 | 0.03 | Why? |
| Neoplasms | 2 | 2019 | 17251 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Living Donors | 1 | 2018 | 652 | 0.03 | Why? |
| Visitors to Patients | 1 | 2020 | 671 | 0.03 | Why? |
| Epstein-Barr Virus Infections | 1 | 2017 | 366 | 0.03 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.03 | Why? |
| History, 20th Century | 1 | 2019 | 1282 | 0.03 | Why? |
| Texas | 1 | 2018 | 1237 | 0.03 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.03 | Why? |
| Drug Monitoring | 1 | 2019 | 1408 | 0.03 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.02 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.02 | Why? |
| Disease Progression | 2 | 2012 | 13580 | 0.02 | Why? |
| Israel | 1 | 2018 | 2751 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Age Factors | 2 | 2019 | 21039 | 0.02 | Why? |
| Graft Rejection | 1 | 2018 | 1766 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Thrombocytopenia | 1 | 2019 | 2093 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| Infant | 2 | 2018 | 30274 | 0.02 | Why? |
| Research | 1 | 2017 | 2115 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2018 | 3755 | 0.02 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.02 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.02 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2019 | 5883 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| France | 1 | 2018 | 12074 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.01 | Why? |
| United States | 2 | 2019 | 46150 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Alanine | 1 | 2018 | 5687 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.01 | Why? |
| Biomarkers | 1 | 2017 | 23361 | 0.01 | Why? |
| Italy | 1 | 2017 | 38444 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Health Personnel | 1 | 2020 | 29646 | 0.01 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |